Skip to main content
LIFECORE BIOMEDICAL, INC. \DE\ logo

LIFECORE BIOMEDICAL, INC. \DE\ — Investor Relations & Filings

Ticker · LFCR ISIN · US5147661046 LEI · 549300EHBZ5OM9ND9O43 US Manufacturing
Filings indexed 1,096 across all filing types
Latest filing 2013-04-12 Director's Dealing
Country US United States of America
Listing US LFCR

About LIFECORE BIOMEDICAL, INC. \DE\

https://www.lifecore.com/

Lifecore Biomedical is an integrated contract development and manufacturing organization (CDMO) that specializes in sterile injectable pharmaceutical drug products and medical devices. The company provides a full range of services, including specialty formulation, process development, aseptic filling, and final packaging, supporting products from clinical phases through to commercial supply. A key area of expertise is the handling of complex and highly viscous formulations. In addition to its CDMO capabilities, Lifecore is a primary producer of non-animal-sourced sodium hyaluronate (hyaluronic acid), offering it in various molecular weights and formats, including bulk material, hydrogels, and filled syringes and vials for diverse applications.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2013-04-12 English
FORM 4
Director's Dealing
2013-04-08 English
FORM 10-Q
Interim / Quarterly Report 9M 2013
2013-04-04 English
FORM 4
Director's Dealing
2013-04-02 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 26, 2013, reporting the issuance of a press release announcing consolidated financial results for the third quarter of fiscal year 2013. The text explicitly states that the press release is furnished as Exhibit 99.1 and is not filed for purposes of Section 18 of the Exchange Act, indicating this is a current report announcing earnings results rather than the earnings release itself. The document length is 3065 characters, which is relatively short and consistent with an 8-K filing announcing earnings results. According to the filing definitions, an initial announcement of quarterly financial results (key highlights only) corresponds to an Earnings Release (ER). However, since this is a Form 8-K furnishing a press release announcing quarterly results, it is best classified as an Earnings Release (ER) because the primary content is the announcement of quarterly financial results. Confidence is high due to explicit mention of quarterly financial results and the nature of the filing as a current report announcing earnings.
2013-03-26 English
FORM 4
Director's Dealing
2013-02-25 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.